Physician profile
Christopher Alexander
NPI 1306850508
$11,285.95
in general payments reported to CMS, 2019-2025
68 companies · $2,826 in 2025
The $2,826 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,618 · 2020: $236 · 2021: $240 · 2022: $1,646 · 2023: $2,129 · 2024: $2,591 · 2025: $2,826.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,407 · Education: $139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,406.95 |
| Education | $139.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,319.38 | 2019-2025 | Kisqali, Piqray |
| Janssen Biotech, INC. | $587.32 | 2019-2025 | Rybrevant, Darzalex, Talvey |
| Genentech USA, INC. | $552.01 | 2019-2025 | Polivy, Venclexta, Tecentriq |
| Pfizer INC. | $530.20 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $493.56 | 2019-2025 | Opdivo |
| Incyte Corporation | $437.05 | 2021-2025 | Monjuvi, Jakafi, Zynyz |
| Abbvie INC. | $423.37 | 2022-2025 | Venclexta |
| Merck Sharp & Dohme LLC | $415.14 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Astellas Pharma US INC | $393.05 | 2019-2025 | Padcev, Vyloy, Xospata |
| Astrazeneca Pharmaceuticals LP | $331.33 | 2019-2025 | Imfinzi, Enhertu, Calquence |
| Glaxosmithkline, LLC. | $307.69 | 2022-2025 | Zejula, Jemperli, Ojjaara |
| Gilead Sciences, INC. | $273.52 | 2021-2025 | Trodelvy |
| Amgen INC. | $258.51 | 2019-2025 | Kyprolis, Kyprolis, Lumakras |
| Eisai INC. | $252.07 | 2019-2025 | |
| Lilly USA, LLC | $247.08 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
Show all 68 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $235.68 | 2019-2025 | Somatuline Depot, Onivyde |
| Takeda Pharmaceuticals U.S.A., INC. | $235.25 | 2019-2025 | Fruzaqla, Iclusig, Ninlaro |
| Tersera Therapeutics LLC | $213.86 | 2023-2025 | Zoladex |
| Kite Pharma, INC. | $213.48 | 2022-2025 | Yescarta |
| Pharmacosmos Therapeutics INC. | $184.69 | 2023-2025 | Monoferric, Cosela |
| Regeneron Healthcare Solutions, INC. | $183.74 | 2019-2025 | Libtayo |
| Pharmacyclics LLC, An Abbvie Company | $174.43 | 2019-2023 | Imbruvica |
| Celgene Corporation | $173.75 | 2019-2025 | Reblozyl |
| Daiichi Sankyo INC. | $155.74 | 2023-2025 | Enhertu, Vanflyta, Datroway |
| Bayer Healthcare Pharmaceuticals INC. | $152.20 | 2021-2025 | |
| Seagen INC. | $142.69 | 2019-2023 | Padcev, Tivdak |
| Servier Pharmaceuticals LLC | $140.11 | 2022-2025 | |
| Abbott Laboratories | $139.51 | 2023 | Proclaim |
| Genzyme Corporation | $133.69 | 2019-2023 | |
| Emd Serono, INC. | $125.72 | 2019-2025 | Bavencio |
| Jazz Pharmaceuticals INC. | $121.31 | 2023-2025 | |
| Array Biopharma INC | $120.94 | 2020-2025 | Mektovi, Braftovi, Lorbrena |
| Taiho Oncology, INC. | $118.99 | 2019-2025 | |
| Sobi, INC | $108.66 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $104.12 | 2019-2024 | Ultomiris |
| Aveo Pharmaceuticals, INC. | $101.66 | 2022-2025 | Fotivda |
| Rigel Pharmaceuticals, INC. | $92.61 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.69 | 2024-2025 | |
| Mirati Therapeutics, INC. | $84.83 | 2023-2024 | Krazati |
| Dendreon Pharmaceuticals LLC | $75.93 | 2025 | Provenge |
| Alnylam Pharmaceuticals INC. | $60.32 | 2019-2025 | Givlaari |
| Exelixis INC. | $60.05 | 2019-2024 | Cabometyx |
| Octapharma USA, INC. | $57.24 | 2022-2025 | Octagam Immune Globulin (Human) |
| Acrotech Biopharma INC. | $41.21 | 2023 | Beleodaq |
| Novocure INC. | $39.45 | 2024-2025 | Optune Lua (Novottf-200t) |
| Stemline Therapeutics INC. | $39.04 | 2024 | Orserdu |
| Tesaro, INC. | $37.70 | 2019 | |
| G1 Therapeutics, INC. | $36.71 | 2023 | Cosela |
| Karyopharm Therapeutics INC. | $35.39 | 2023 | Xpovio |
| Delcath Systems | $34.04 | 2025 | Hepzato Kit |
| Puma Biotechnology, INC. | $33.32 | 2025 | |
| Aurobindo Pharma USA, INC. | $31.83 | 2019 | |
| Beone Medicines USA, INC. | $29.80 | 2025 | Brukinsa |
| Apellis Pharmaceuticals, INC. | $29.19 | 2023-2024 | Empaveli |
| Horizon Therapeutics Plc | $26.02 | 2019 | |
| Pharmaessentia USA Corporation | $25.30 | 2025 | Besremi |
| Adaptive Biotechnologies Corporation | $24.51 | 2025 | Clonoseq |
| Janssen Pharmaceuticals, INC | $24.16 | 2019-2024 | Xarelto |
| Coherus Oncology, INC. | $22.55 | 2024 | |
| Recordati_rare_diseases_inc. | $21.91 | 2023 | Sylvant |
| Adc Therapeutics America, INC. | $19.62 | 2022 | |
| Clovis Oncology, INC. | $19.23 | 2019 | |
| Tolmar, INC. | $18.55 | 2023 | |
| Sanofi-Aventis U.S. LLC | $17.65 | 2019 | |
| Agios Pharmaceuticals, INC. | $16.11 | 2019 | |
| Syndax Pharmaceuticals, INC. | $15.85 | 2025 | |
| Cti Biopharma Corp. | $14.33 | 2023 | Vonjo |
| Macrogenics, INC. | $13.31 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Alexander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.